Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001955678 | SCV002223368 | uncertain significance | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A13 | 2022-06-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with B4GAT1-related conditions. This variant is present in population databases (rs774850290, gnomAD 0.0009%). This sequence change replaces methionine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 230 of the B4GAT1 protein (p.Met230Leu). |
Ambry Genetics | RCV002562867 | SCV003632835 | uncertain significance | Inborn genetic diseases | 2022-07-22 | criteria provided, single submitter | clinical testing | The c.688A>C (p.M230L) alteration is located in exon 1 (coding exon 1) of the B4GAT1 gene. This alteration results from a A to C substitution at nucleotide position 688, causing the methionine (M) at amino acid position 230 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |